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Abstract The anti-angiogenic agents angiostatin and endosta-
tin have been shown to a¡ect endothelial cell migration in a
number of studies. We have examined the e¡ect of these agents
on intracellular signalling pathways known to regulate endothe-
lial cell migration and proliferation/survival. Both agents inhib-
ited ¢broblast growth factor (FGF)-, and vascular endothelial
growth factor (VEGF)-mediated migration of primary human
microvascular endothelial cells and a¡ected vascular formation
in the embryoid body model. However, using phosphospeci¢c
antibodies we could not detect any e¡ect of angiostatin or endo-
statin on phospholipase C-Q (PLC-Q), Akt/PKB, p44/42 mito-
gen-activated protein kinase (MAPK), p38 MAPK and p21-ac-
tivated kinase (PAK) activity. Furthermore, using a glutathione
S-transferase (GST)-PAK pull-down assay, we could not detect
any e¡ect on Rac activity. We conclude that angiostatin and
endostatin inhibit chemotaxis, without a¡ecting intracellular
signalling pathways known to regulate endothelial migration
and proliferation/survival.
5 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Angiogenesis denotes the formation of new blood vessels
from preexisting vessels. This physiological process is involved
in embryonic development and the menstrual cycle. It is also
involved in pathological conditions such as tumour progres-
sion, rheumatoid arthritis and diabetic retinopathy. Angiogen-
esis is stimulated by a number of angiogenic factors, including
¢broblast growth factor (FGF) and vascular endothelial
growth factor (VEGF) [1,2]. These angiogenic factors bind
to their cognate receptor expressed on the surface of endothe-
lial cells and evoke an intracellular signalling response, culmi-
nating in the proliferation, migration and eventual di¡erentia-
tion of endothelial cells to form lumen-containing vessels.
The potential pharmacological regulation of angiogenesis is
now an area of intense interest. In 1994, O’Reilly et al. de-
scribed a 38 kDa fragment of plasminogen called angiostatin
(AS), which was puri¢ed from mice bearing a Lewis lung
carcinoma [3]. AS inhibits tumour angiogenesis and induces
tumour dormancy by inhibiting endothelial cell proliferation
[4] and by inducing apoptosis [5,6]. AS has been shown to
bind and block K/L-ATP synthase on the surface of endothe-
lial cells, inhibiting proliferation [7], whilst another study has
described an AS binding protein, termed angiomotin, which is
required for AS to inhibit endothelial cell chemotaxis [8]. In
1997, O’Reilly et al. isolated endostatin (ES), a 20 kDa frag-
ment of the C-terminal part of the collagen XVIII K1-chain
[9]. ES has been reported to bind to Kv- and K5-integrins [10]
and to a low a⁄nity glypican type receptor [11]. Whilst a
number of studies of AS and ES action have shown an a¡ect
on endothelial cell chemotaxis [12,13], no studies so far have
addressed the e¡ect of these compounds on pathways known
to regulate cellular migration.
The migration of endothelial cells is a critical component of
the angiogenic response, where cells must digest the basement
membrane, migrate and proliferate to form a new lumen-con-
taining vessel. Cellular migration is regulated in a spatial and
temporal manner by Rho family GTPases [14]. In this paper
we have examined the e¡ect of AS and ES on a number of
intracellular pathways implicated in endothelial cell physiol-
ogy. We report that whilst AS and ES can a¡ect cellular
migration of primary endothelial cells and vascular develop-
ment in embryoid bodies, there is no apparent e¡ect on intra-
cellular pathways known to regulate cellular migration and
proliferation. We conclude that both AS and ES have a novel
e¡ect in perturbing cellular migration.
2. Materials and methods
2.1. Antibodies and reagents
Phosphospeci¢c rabbit polyclonal antibodies against p44/42 MAPK
(Thr-202/Tyr-204), p38 MAPK (Thr-180/Tyr-182) Akt/PKB (Ser-473),
PLC-Q (Tyr-783) and PAK (PAK1 Thr-423, PAK2 Thr-402) were
purchased from Cell Signalling. The monoclonal anti-Rac clone
23A8 was purchased from Upstate Biotechnology. Recombinant hu-
man FGF-2 was purchased from Boehringer Mannheim (Mannheim,
Germany) and recombinant human VEGF-A165 and recombinant hu-
man platelet-derived growth factor (PDGF-BB) were purchased from
Peprotech (England). Bovine type I collagen was purchased from
Vitrogen (Cohesion Technologies, USA). Recombinant human AS
and ES, puri¢ed from Pichia pastoris, were provided by Entremed
(Rockville, MD, USA). Endotoxin level for AS was 0.002 EU/mg
whilst that for ES was undetectable.
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2.2. Cell culture
Human dermal microvascular endothelial cells (HDMECs) were
isolated from neonatal foreskin as previously described [15]. Cells
were routinely cultured on gelatin-coated plastic dishes in endothelial
basal media (EBM; Clonetics, USA) containing 10% foetal calf serum
(FCS) and 2 ng/ml FGF-2.
2.3. Chemotaxis assay
Chemotaxis was analysed essentially as described [13] using a 48-
well modi¢ed Boyden chemotaxis chamber (Neuro Probe, Cabin
John, USA). Polycarbonate membranes (pore size 8 WM, polyvinyl-
pyrrolidone-free) were coated with bovine collagen type I (150 Wg/ml).
HDMECs were starved in EBM containing 1% FCS overnight. The
cells were trypsinised, resuspended in EBM containing 0.1% bovine
serum albumin (BSA) and either AS or ES and placed in the upper
chamber. Either FGF or VEGF, with or without AS or ES, was
placed in the lower chamber and cells were allowed to migrate to-
wards this for 4 h at 37‡C. The number of cells that had migrated to
the lower surface of the membrane were counted in three ¢elds using
U400 magni¢cation. Samples were analysed in triplicate on three
separate occasions.
Fig. 1. E¡ect of AS and ES on vascular development in EBs. A: Murine embryonal stem cells were allowed to di¡erentiate into EBs in the ab-
sence or presence of FGF-2. Bodies were incubated with either AS (3 Wg/ml) or ES (3 Wg/ml) and were allowed to develop for 12 days. Endo-
thelial cells were visualised by staining for CD31. Pictures shown are U10 magni¢cation. Higher magni¢cations (U50) of speci¢c areas from
the FGF-stimulated conditions are shown. Bars represent 500 Wm. B: The amount of CD31 staining was quanti¢ed. Results are expressed as
the percentage of basal staining (meanPS.D., n=3) from a single experiment representative of three. *P6 0.05 compared with FGF alone, as
determined using Student’s t-test for unpaired data.
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2.4. Embryoid bodies
The mouse embryonal stem cell line R1, derived from the strain
SvJ129, was a kind gift of Dr. A. Nagy (Samuel Lunenfeld Research
Institute, Mount Sinai Hospital, Toronto, ON, Canada). Embryonal
stem cells were cultured in medium composed of Dulbecco’s modi¢ed
Eagle’s medium/glutamax (Invitrogen, Rockville, MD, USA) supple-
mented with 15% heat-inactivated FCS, 25 mM HEPES, 1.2 mM Na-
pyruvate (Invitrogen), 19 WM monothioglycerol (Sigma, St. Louis,
MO, USA) and 1000 U/ml recombinant leukaemia inhibitory factor
(LIF; Chemicon International, Harrow, UK). Cells were cultured at
37‡C with 5% CO2. Medium was changed every day and splitting was
done every second or third day. To induce di¡erentiation, LIF was
withdrawn from the medium. Aggregation was induced by placing 20
Wl drops of 1200 cells on the lid of a non-adherent tissue culture dish
in the presence or absence of FGF-2 (20 ng/ml). The day when LIF
was removed from the media and droplets were formed was denoted
day 0. The drops were left hanging on the lid for 4 days, in 37‡C and
5% CO2, whereafter they were plated one by one in eight-well glass
culture slides (Falcon, Frankling Lakes, NJ, USA) in the presence or
absence of FGF-2. The inhibitors AS (3 Wg/ml) or ES (3 Wg/ml) were
added as indicated. Media including inhibitors were changed every
fourth day. On day 12, the embryoid bodies (EBs) were ¢xed for 10
min in 4% paraformaldehyde, blocked for endogenous peroxidase and
non-speci¢c binding before incubation of primary antibody rat anti-
mouse CD31 (Becton Dickinson (BD) Biosciences, Erembodegem,
Belgium) overnight at 4‡C. Secondary biotinylated antibody goat
anti-rat IgG (Vector Laboratories, Burlingame, CA, USA) was added
followed by streptavidin^horseradish peroxidase (HRP) (Vector) and
the chromogen substrate, 3-amino-9-ethylcarbazole (AEC; Vector
Laboratories). Pictures were taken with an inverted Nikon Eclipse
Microscope (Nikon, Kanagawa, Japan). Quanti¢cation of CD31
staining was performed with Easy Image analysis software (Tekno
Optik AB, Stockholm, Sweden).
2.5. Western blotting
Cells were seeded at 2U105 cells per well of gelatin-coated six-well
plates in growth medium and cultured for 48 h at 37‡C. The medium
was changed to EBM containing 1% FCS and cells incubated for
another 24 h at 37‡C. Cells were stimulated with agonist, rinsed in
ice-cold phosphate-bu¡ered saline (PBS) and lysed in 250 Wl Laemmli
sample bu¡er containing 1 mM phenylmethylsulphonyl £uoride
(PMSF). Lysates were sonicated for 5 s, heated at 95‡C for 5 min
and centrifuged at 14 000Ug for 15 min. Supernatant was transferred
to a fresh Eppendorf tube. Approximately 50 Wg of total cellular
protein was resolved by sodium dodecyl sulphate^polyacrylamide
gel electrophoresis (SDS^PAGE) using a 10% gel. Proteins were de-
tected by Western blotting as previously described [16].
2.6. Analysis of Rac activation
Escherichia coli harbouring the plasmid pGEX2TK containing the
PAK-Crib domain (56^272) fused to glutathione S-transferase (GST)
was kindly provided by Dr. Collard (Netherlands Cancer Institute).
Fusion protein was puri¢ed as previously described [16]. For the anal-
ysis of Rac activation, cells were washed in ice-cold PBS and lysed in
50 mM Tris^HCl pH 7.4 containing 10 mM MgCl2, 10% glycerol, 150
mM NaCl, 1% Triton X-100, 1 mM PMSF, 10 Wg/ml aprotinin and 10
Wg/ml leupeptin. Lysates were clari¢ed by centrifugation and approx-
imately 500 Wg of total cellular protein incubated with 50 Wg of GST-
Pak-Crib domain fusion protein for 1 h at 4‡C with end-over-end
mixing. The beads were collected by centrifugation and washed four
times in lysis bu¡er. The beads were resuspended in Laemmli sample
bu¡er and boiled for 5 min. Proteins were resolved by SDS^PAGE
using a 15% gel, transferred electrophoretically and visualised using
electrochemoluminescence (ECL).
2.7. Thymidine assay
Mitogenicity was determined by the incorporation of [3H]thymidine
as previously described [16].
3. Results and discussion
3.1. AS and ES a¡ect angiogenesis in the embryoid body model
Embryoid bodies (EBs) are murine embryonic stem cells
which develop vascular structures in response to treatment
with angiogenic growth factors. The EBs have been shown
to represent a useful in vitro model of angiogenesis [17]. In
the presence of FGF-2, a characteristic twisted network of
long and slender vessels is formed. We were interested in
the ability of AS and ES to a¡ect the endothelial vasculature
in the EBs. Fig. 1A shows the characteristic capillary plexus of
endothelial cells in the presence of FGF-2. When AS was
added to the culture, in the presence of FGF-2, the vessel
network appeared truncated and disjointed, although the
number of endothelial cells were not a¡ected, compared to
FGF-2 alone (Fig. 1B). In the presence of ES, the plexus
was considerably reduced and the vessels were thinner and
more stretched. The number of endothelial cells were reduced
to basal levels in the presence of ES (Fig. 1B).
3.2. AS and ES inhibit the migration of human endothelial cells
stimulated with FGF and VEGF
AS and ES have been previously shown to a¡ect a number
of endothelial responses including cellular migration, which
may explain the anti-angiogenic e¡ects of these agents in
vivo. We utilised human dermal microvascular endothelial
cells (HDMECs) to study the e¡ect of both agents on FGF-
Fig. 2. E¡ect of AS and ES on endothelial cell chemotaxis.
HDMECs were preincubated with either AS (3 Wg/ml) or ES (3 Wg/
ml) for the times shown. Cells were allowed to migrate towards ei-
ther, A: FGF (10 ng/ml), or B: VEGF (30 ng/ml), using a modi¢ed
Boyden chamber for 4 h at 37‡C. Results are expressed as the per-
centage of basal response (meanPS.D., n=3) from a single experi-
ment representative of three. *P6 0.01 compared with either FGF
or VEGF alone, as determined using Student’s t-test for unpaired
data.
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and VEGF-stimulated cell migration. Fig. 2 shows that both
AS and ES inhibited HDMEC migration in response to FGF
and VEGF. Preincubation with the inhibitors for either 2 or
24 h produced a similar e¡ect in inhibiting migration, con-
¢rming that long-term exposure to these agents was not re-
quired to a¡ect migration.
3.3. AS and ES do not a¡ect intracellular signalling pathways
stimulated by FGF and VEGF
FGF and VEGF stimulate a number of intracellular signal-
ling pathways leading to an angiogenic response in endothelial
cells [1,2]. We sought to determine if AS and ES a¡ected a
number of these signalling pathways which may explain their
known e¡ects on endothelial cells. Analysis of the tyrosine
phosphorylated proteins in cell extracts from FGF- and
VEGF-stimulated HDMECs (Fig. 3A), revealed that FGF
induced the phosphorylation of proteins of approximately
90 and 42 kDa, probably FGF-receptor substrate 2 (FRS2)
and p42 MAPK respectively. VEGF induced a weaker phos-
phorylation of only the 42 kDa protein. Preincubation with
either AS or ES did not a¡ect the tyrosine phosphorylation
status of these proteins (Fig. 3A). Using phosphospeci¢c anti-
bodies, we analysed the phosphorylation status of a number
of intracellular signalling molecules known to be activated by
either FGF and/or VEGF. We were interested in speci¢c pro-
teins such as PLC-Q which has been implicated in FGF-medi-
ated cytoskeletal reorganisation [18] and VEGF-mediated mi-
togenicity [19], Akt/PKB which is known to regulate cell
survival, p44/42 MAPK which regulates mitogenicity [1],
and p38 MAPK implicated in FGF-mediated di¡erentiation
[20] and VEGF-mediated migration [21]. Fig. 3B shows that
neither AS nor ES a¡ected the phosphorylation status of
PLC-Q, Akt, p44/42 MAPK and p38 MAPK in response to
FGF and VEGF in HDMECs, suggesting that these anti-an-
giogenic agents did not a¡ect pathways regulating cell survival
and mitogenicity in endothelial cells. In an attempt to study
AS and ES action under identical conditions as during migra-
tion, we also plated HDMECs onto collagen type I-coated
plates and incubated them with either AS or ES for 2 and
24 h. Analysis of the intracellular phosphorylation status of
PLC-Q, Akt, p44/42 MAPK and p38 MAPK following FGF
or VEGF stimulation revealed that AS and ES treatment
showed no e¡ect (data not shown).
We next determined the direct e¡ect of AS and ES on
HDMEC mitogenicity by measuring [3H]thymidine incorpo-
ration in response to FGF and VEGF. However, only FGF-2
was able to evoke a mitogenic response in these cells (Fig. 4).
Neither AS nor ES a¡ected FGF-2-stimulated mitogenicity,
further supporting their lack of e¡ect on pathways such as
MAPK (Fig. 3). Both AS and ES were originally reported
to inhibit the growth of bovine capillary endothelial cells
[3,9]. However, recent data have shown that AS does not
a¡ect FGF- or VEGF-mediated mitogenicity in human um-
bilical vein cells [22]. Taken together with our data, it is pos-
Fig. 3. E¡ect of AS and ES on intracellular signalling pathways. HDMECs were preincubated with either AS (3 Wg/ml) or ES (3 Wg/ml) for the
times shown. Cells were stimulated with either FGF (10 ng/ml) or VEGF (30 ng/ml), lysed and proteins separated by SDS^PAGE followed by
Western blotting. A: Analysis of tyrosine phosphorylation of cellular proteins. Arrows indicate bands of approximately 90 and 42 kDa.
B: Analysis of the phosphorylation status of PLC-Q, Akt/PKB, p44/42 MAPK and p38 MAPK. Actin is used as a loading control. Results
shown are representative of three separate experiments.
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sible that the e¡ect of AS and ES on proliferation is cell type
speci¢c.
3.4. AS and ES do not a¡ect Rac and PAK activity in response
to VEGF and PDGF
Cellular migration is a complex process involving lamellipo-
dium extension, formation of new adhesions, cell body con-
traction and tail detachment [14]. The small molecular weight
GTPase Rac is responsible for regulating lamellipodium for-
mation, and focal complex assembly, in response to growth
factors which stimulate cell migration [23]. Rac activity is
spatially and temporally regulated by the lipid products of
phosphoinositide 3-kinase (PI3-kinase) activity [24,25]. We
analysed the GTP status of cellular Rac in response to growth
factors by using a PAK-Crib-GST fusion protein pull-down
assay to speci¢cally isolate GTP-bound Rac. We found that in
HDMECs, Rac was transiently activated by both VEGF and
PDGF. In contrast, Rac did not appear to be activated by
FGF in these cells (data not shown). Preincubation with both
AS and ES did not a¡ect the activation status of Rac in
response to VEGF and PDGF (Fig. 5A). Addition of wort-
mannin, a known PI3-kinase inhibitor, prevented activation of
Rac in response to both VEGF and PDGF. Taken together,
these data suggest that AS and ES do not a¡ect growth fac-
tor-stimulated PI3-kinase/Rac activity, and therefore have a
unique action in inhibiting cellular migration.
Active Rac is known to bind to the serine/threonine kinase
PAK resulting in the phosphorylation of PAK and the acti-
vation of a number of signalling cascades [26]. Using a phos-
phospeci¢c antibody, we determined the e¡ect of AS and ES
on the activation status of PAK. Fig. 5B shows that neither
AS nor ES a¡ected the phosphorylation of PAK in response
to VEGF, further con¢rming their inability to a¡ect the Rac
cascade.
In this study, we have demonstrated that AS and ES do not
a¡ect the key intracellular signalling cascades implicated in
cellular migration and proliferation. Recent data have sug-
gested that ES may disturb endothelial cell^matrix interac-
tions by transiently blocking the association of L-catenin
and paxillin [27] and by binding to integrin K5L1 and caveo-
lin-1 [28]. Therefore, it would seem probable that AS and ES
disrupt cellular migration via subtle e¡ects on the cell matrix.
The inability of AS and ES to a¡ect intracellular signalling
pathways probably re£ects the low toxicity of these agents in
the clinic, where anti-angiogenic e¡ects have been observed in
the absence of systemic toxicity in the vasculature. Whilst
both AS and ES have the ability to a¡ect cellular migration,
their ability to di¡erentially a¡ect the vasculature in the em-
bryoid body model suggests they have di¡erent mechanisms of
action.
Fig. 5. E¡ect of AS and ES on Rac and PAK activation. A: HDMECs were preincubated with both AS (3 Wg/ml) and ES (3 Wg/ml) for the
time periods shown. Cells were also preincubated with wortmannin (500 nM) for 30 min. Cells were stimulated with either VEGF (30 ng/ml)
or PDGF (30 ng/ml), lysed and Rac activity determined by use of a GST-PAK-Crib domain pull-down as described in Section 2. B: HDMECs
were preincubated with either AS (3 Wg/ml) or ES (3 Wg/ml) for the periods shown. Cells were stimulated with VEGF (30 ng/ml), lysed and pro-
teins separated by SDS^PAGE followed by Western blotting. Actin is used as a loading control. Results shown are representative of two sepa-
rate experiments.
Fig. 4. E¡ect of AS and ES on mitogenicity. HDMECs were stimu-
lated with either FGF (10 ng/ml) or VEGF (30 ng/ml) for 20 h in
the presence of either AS (3 Wg/ml) or ES (3 Wg/ml). Mitogenicity
was measured by [3H]thymidine incorporation. Results are expressed
as [3H]thymidine incorporation (meanPS.D., dpm n=3) from a sin-
gle experiment representative of three.
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